Table 4.
Efficacy of 1125 mg telaprevir BID plus PegIFNα/RBV for 12w + PegIFNα/RBV for 12w or 36w.
| Cirrhosis | Prior treatment | SVR12 rate in GT-1 | Study and trial phase | Ref. |
|---|---|---|---|---|
| No cirrhosis |
Naïve | 1a: 82.3% (28/34), 1b: 78% (32/41) | MALACHITE-I, phase 3 | Dore et al., 2016a |
| Null response | 56.5% (13/23) | MALACHITE-II, phase 3 | ||
| Partial response | 75% (9/12) | |||
| Relapse | 75% (9/12) | |||
| Null response | 50% (95/190) | ATTAIN, phase 3 | Reddy et al., 2015a | |
| Partial response | 72.3% (86/119) | |||
| Naïve | 62.2% (69/111) | Phase 3 | Kumada et al., 2016 | |
| Naïve | 77.78% (245/315) | OPTIMIZE, phase 3 | Buti et al., 2014 | |
| Naïve | 61.8% (272/440) a | HCV-TARGET, phase 3 |
Sterling et al., 2015 |
|
| Experienced | 59.3% (300/506) a | |||
| Cirrhosis | Naïve | 53.7% (29/54) | OPTIMIZE, phase 3 | Buti et al., 2014 |
| Naïve | 43.5% (103/237) a | HCV-TARGET, phase 3 | Sterling et al., 2015 | |
| Experienced | 48.4% (194/401) a | |||
| Null response | 31.3% (15/48) | ATTAIN, phase 3 | Reddy et al., 2015a | |
| Partial response | 51.9% (14/27) | |||
| Relapse | 74.2% (92/124) | ANRS CO20, phase 3 | Hezode et al., 2014 | |
| Partial response | 40% (54/135) | |||
| Null response | 19.4% (6/31) | |||
1a: HCV genotype 1a, 1b: HCV genotype 1b.
a
SVR24 rates were evaluated in the clinical study.